Метаболічний синдром – одне з найбільш складних питань медицини в XXI ст. Представлено сучасні дані діагностики та заходи з його корекції та профілактики.

Ефективність успішного лікування хворих із МС прямо пропорційно зв’язана зі зміною способу життя, що має на меті зниження маси тіла. Хоча не у всіх немедикаментозне лікування дає позитивні зміни. Тоді препаратом вибору є метформін, завдяки якому купіруються основні прояви МС. Сьогодні немає єдиного визнаного методу лікування МС. Із огляду на це, розроблення нових методів лікування і нагляду, вибору оптимальних препаратів для лікування МС є актуальною проблемою медицини.

Ключові слова: метаболічний синдром, фактори ризику, діагностика, лікування, профілактика, метформін

Повний текст: PDF (Eng)

1. 1. Ambrosova T. Effect of metformin in type 2 diabetes: cardiovascular, protective and metabolic. Eksperymentalna i klinichna medytsyna. 2013;3:35-40.
2. 2. Belalov F. Treatment of internal diseases in terms of comorbidity. Irkutsk:2012. 283.
3. 3.Gumenuk A. View on the problem of rational treatment of patients with cardiovascular pathology and polymorbid conditions. Ukr.med. Chasopys. 2009;5(73):25-32.
4. 4. Kozlovskyj V. Differential pharmacotherapy comorbid of anxiety and depression. Saint Peterburg: 2012.4-6.
5. 5. Kostina V, Ziuzin V, Zinchenko T. Metabolic syndrome: methods of diagnostic and rehabilitation. Naukovi pratsi. 2011;152(140):76-78.
6. 6. Liashuk R, Liashuk P, Hluhovska S.Comorbidity of metabolic syndrome and sleep apnea. Bukovynskyi medychnyi visnyk. 2015;19(3):273–275.
7. 7. Mitchenko O, Karpachov V. Diagnosis and treatment of metabolic syndrome, diabetes, prediabetes and cardiovascular disease: recommendations Association of Cardiologists of Ukraine and the Association of Endocrinologists of Ukraine. Sertsevo-sudynni zakhvoriuvannia: rekomendatsii z diahnostyky, profilaktyky ta likuvannia: Za red. V.M. Kovalenka, M.I. Lutaia; 2011;68-79.
8. 8. Mitchenko O,Korpachev V. Diagnosis and treatment of metabolic syndrome, diabetes, prediabetes and cardiovascular disease.Methodological recommendations. 2009;6-24.
9. 9. Sakevich V, Tribrat T, Shut S. Atopy and metabolic syndrome: the rationale of pathogenetic approaches to diagnosis, treatment and prevention.Visnyk problem biolohii i medytsyny. 2014;4(3):30-33.
10. 10. Sokolova L.Metabolic Syndrome and Associated Diseases: Diagnostic Criteria and Therapeutic Approaches. Review of the Literature and Analysis of the Author's Data.Liky Ukrainy.2012;10:4-19.
11. 11. Tkachenko E, Uspenskyj Y, Belousova L. Nonalcoholic fatty liver disease and metabolic syndrome. Eksperym. Iklin. gastroenterologia. 2008;2:92-96.
12. 12. Fonseka V. Metabolic syndrome. Moscow. 2011;86-87.
13. 13. Chopei I, Mosiuk D, Korsak I. Quality of life evaluation in patient with metabolic syndrome. Naukovyi visnyk Uzhhorodskoho universytetu, Seriia «Medytsyna». 2013;1(46):57-59.
14. 14. Shlahto E, Konrady A. Epidemiology of metabolic syndrome in different regions. Dependence on the criteria used and predictive value. Hypertension.2007;13(2):95-112.
15. 15. Shut S.Factors which affect to the development of metabolic syndrome.Visnyk problem biolohii medytsyny.2015;1(118):63-67.
16. 16. Abbate S. Hypertension in diabetes: Controlling a critical comorbid condition. Diabetes Spectrum.2006;19(1):17.
 doi.org/10.2337/diaspect.19.1.17
17. 17. Alberti K, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition.Lancet.2005;366(9491):1059-1062.
 doi.org/10.1016/S0140-6736(05)67402-8
18. 18. Al-Nasiry, Ghossein-Doha, Polman et al. Metabolic Syndrome after Pregnancies Complicated by Pre-Eclampsia or Small for Gestational Age: A Retrospective Cohort. 2014. BJOG, EpubAheadofPrint. doi.org/10.1111/1471-0528.13117
19. 19. American Diabetes Association.Screening for type 2 diabetes.Diab.Care.2000;23(1):20-23.
20. 20. Campbell-Scherer D. Multimorbidity: a challenge for evidence-based medicine.Evid.Based Med.2010;15(6):165-166.
 doi.org/10.1136/ebm1154
21. 21. Caughey G, Ramsay E, Vitry A, Glibert A, Luszcz M, Ryan P et al. Comorbid chronic diseases, discordant impact on mortality in older people: a 14-year longitudinal population study. J. Epidemiol. Community Health. 2010;64(12):1036-1042.
 doi.org/10.1136/jech.2009.088260
22. 22.Caughey G,Roughead E. Multimorbidity research challenges: where to go from here?Journal of Comorbidity.2011;1:8-10.
 doi.org/10.15256/joc.2011.1.9
23. 23. Ceballos L. Metabolic Syndrome en la Childhood.Anales de pediatría.AEP.2007;66:159-166.
24. 24.Cífková R. Epidemiologie metabolického syndromu ve světě a v České republice. Praha:Ústní sdělenína Symposiu o syndromu inzulínové rezistence; 2003.26-27.
25. 25. Corbatón-Anchuelo A, Martínez-Larrad M, Fernández-Pérez C, Vega-Quiroga S, Ibarra-Rueda J, Serrano-Ríos M. Metabolic Syndrome, Adiponectin, and Cardiovascular Risk in Spain (the Segovia study). Impact of Consensus Societies Criteria.MetabSyndrRelatDisord. 2013;11(5): 309-318.
doi.org/10.1089/met.2012.0115
26. 26. Deen D. Metabolic syndrome: time fo raction,The American Family Physician. 2004;69(12):2875-2887.
27. 27. De Flines J, Scheen A. Management of metabolic syndrome and associated cardiovascular risk factors. Acta Gastroenterol Belg.2010;73(2):261-266.
28. 28. Diabetes Prevention Program Research Group. Reduction in the incidence oftype 2 diabetes with lifesyill intervention or metformin. N Engl J Med.2002;346:393-403.
 doi.org/10.1056/NEJMoa012512
29. 29. Kassi E, Panagiota P, Gregory K, George C. Metabolic Syndrome: Definitions and Controversies.BMCMedicine.2011; 9-48. http://dx.doi.org/10.1186/1741-7015-9-48.
 doi.org/10.1186/1741-7015-9-48
30. 30. Ford E, Zhao G. Prevalence and Correlates of Metabolic Syndrome Based on a Harmonious Definition among Adults in the US.J Diabetes.2010;2:180-193.
 doi.org/10.1111/j.1753-0407.2010.00078.x
31. 31. Girvalaki Ch, Vardavas C, Papandreou Ch, Kafatos A.Trends in Metabolic Syndrome Risk Factors among Adolescents in Rural Crete between 1989 and 2011.Hormones.2014;13(2):259-267.
32. 32. Hamilton dos Prazeres Tavares, Mariana Alvarez Arantes, Suelma Beatriz Marques Prata Tavares,Joelcio Francisco Abbade,Débora Cristina DamascenoMeirelles dos Santos,Iracema de MattosParanhos Calderonet al.Metabolic Syndrome and Pregnancy, Its Prevalence, Obstetrical and Newborns Complications.Open Journal of Obstetrics and Gynecology. 2015;5:618-625.
 doi.org/10.4236/ojog.2015.511087
33. 33. ICD–9–CMCoordinationandMaintenanceCommitteeMeeting. 2000;11:2-3.
34. 34. Kaur J. A Comprehensive Review on Metabolic Syndrome.Cardiology Research and Practice.2014;1-21.
 doi.org/10.1155/2014/943162
35. 35. Martino F, Pannarale G, Puddu P, Colantoni C, Zanoni C, Martino E et al. Is it possible a new definition of metabolic syndrome in childhood? Eur Rev Med Pharmacol Sci.2015;19(22):4324-4331.
36. 36.Reaven G. Role of insulin resistance in human disease.Diabetes.1988;37(12):1595-1607.
 doi.org/10.2337/diab.37.12.1595
37. 37. Saely C, Koch L, Schmid F, Marte T, Aczel S, Langer P et al. Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 Criteria of the Metabolic Syndrome Predict Clinical Cardiovascular Events in Subjects Who Underwent Coronary Angiography.Diabetes Care.2006;29:901-907.
 doi.org/10.2337/diacare.29.04.06.dc05-2011
38. 38. Singh A, Kari J. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2013; 22(2):198-203.
 doi.org/10.1097/MNH.0b013e32835dda78
39. 39. Stumvoll M, Nurjhan N, Perriello G, Dailey G,Gerich E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.N. Eng J Med.1995; 333:550-554.
 doi.org/10.1056/NEJM199508313330903
40. 40. Sun G, Kashyap S. Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. J. Nutr. Metab.2011.70-183.
41. 41. Teixeira Metabolic Syndrome in Pregnancy as Predictor of Adverse Obstetric and Neonatal Outcomes. Master's Dissertation. Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto. 2009. www.icbas.up.pt/biblioteca/images/.../boletim%20bibliogrfico03.pdf.
42. 42. The IDF consensus worldwide definition of the METABOLIC SYNDROME, International Diabetes Federation, Belgium.2006.14-19.
43. 43. Tkač I. Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis. Diabetes Res ClinPrac. 2005;68:2-9.
 doi.org/10.1016/j.diabres.2005.03.002
44. 44. Turner R.The U.K. Prospective Diabetes Study.A review.Diabetes Care.1998;21:35-38.
 doi.org/10.2337/diacare.21.3.C35
45. 45. Vernay M,Salanave B, de Peretti C, Druet C, Malon A, Deschamps V at al. Metabolic Syndrome and Socioeconomic Status in France. The French Nutrition and Health Survey (ENNS, 2006–2007). International Journal of Public Health.2013;58:855-864.
 doi.org/10.1007/s00038-013-0501-2
46. 46. Vishram J, Borglykke A, Andreasen A, Jeppesen J, Ibsen H, JørgensenTet al. Impact of Age and Gender on the Prevalence and Prognostic Importance of the Metabolic Syndrome and Its Components in Europeans. The MORGAM Prospective Cohort Project.2014.9. doi.org/10.1371/journal.pone.0107294